Beijing SL Pharmaceutical Co., Ltd.
Symbol: 002038.SZ
SHZ
8.62
CNYMarktpreis heute
31.0841
P/E-Verhältnis
2.4867
PEG-Verhältnis
8.86B
MRK Kapital
- 0.01%
DIV Rendite
Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5056.78 | 2133 | 739.9 | 990.2 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | 2289.51 | 1449.2 | 144.9 | 162.4 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 1134.59 | 236.2 | 406.4 | 534 | |||||||||||||||||||||||
balance-sheet.row.inventory | 625.05 | 144.5 | 136.8 | 124.8 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 2585.99 | 126.3 | 714.5 | 648.7 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 9402.41 | 2640 | 1997.7 | 2297.7 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 2044.8 | 538.4 | 527.3 | 604 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 4425.3 | 1143.7 | 978.5 | 872.8 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 5601.25 | 1587.3 | 1295.1 | 1241.3 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 77.69 | 0 | 39.5 | 27.7 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3192.71 | 368.4 | 1037.7 | 717 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 15341.75 | 3637.8 | 3878.2 | 3462.7 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 778.6 | 213.2 | 176.2 | 191.4 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 46.32 | 37.6 | -27.9 | 0.2 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 11.48 | 0 | 9 | 16.3 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
Deferred Revenue Non Current | 185.63 | 47 | 51.4 | 56.2 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 223.42 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 379.81 | 107.3 | 112.7 | 1.6 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 362.01 | 47.4 | 107.8 | 109.3 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 2.2 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 1621.95 | 420.7 | 396.6 | 434.2 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 4109.4 | 1027.3 | 1027.3 | 1027.3 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 16182.54 | 4077.8 | 3763.8 | 3632.1 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2743.99 | 695.1 | 676.5 | 651.9 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0.86 | 0.4 | 0.4 | 0.1 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 23036.79 | 5800.6 | 5468.1 | 5311.5 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 24744.16 | 6277.8 | 5875.8 | 5760.5 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 38.37 | 9.4 | 11.2 | 14.7 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 23075.16 | 5810 | 5479.2 | 5326.2 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 24744.16 | - | - | - | |||||||||||||||||||||||
Total Investments | 7890.75 | 3036.4 | 1440.1 | 1403.6 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 75.19 | 37.6 | 0 | 2.5 | |||||||||||||||||||||||
balance-sheet.row.net-debt | -2692.08 | -646.2 | -595 | -825.4 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 284.9 | 228.3 | 421.3 | 361.5 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 6.41 | 113.9 | 99.8 | 89.5 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.3 | -14.4 | -25.6 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 15.41 | 113.7 | 129.1 | 197.9 | ||||||||||||||||||||
cash-flows.row.account-receivables | 19.66 | 82.9 | 108.6 | 198.8 | ||||||||||||||||||||
cash-flows.row.inventory | -4.25 | 0.6 | -11.5 | -3.7 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 36.6 | 17.5 | -22.7 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.3 | 14.4 | 25.6 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 269.47 | -66.1 | -185.6 | -233.1 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 481.62 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.01 | -3.4 | 16.5 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -582.01 | -1247.4 | -1061 | -1517.2 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 487.59 | 896.1 | 1092.6 | 964.3 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -71.42 | -22.2 | -9 | -33.3 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -383.53 | -540.4 | -197.8 | -842.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -11 | -5.6 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -102.7 | -102.9 | -205.8 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 10.6 | 4.5 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -110.25 | -102.7 | -103.3 | -206.9 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.03 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -153.55 | -253.2 | 163.5 | -633.1 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 2465.46 | 527.2 | 780.4 | 617 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2619.01 | 780.4 | 617 | 1250.1 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 481.62 | 389.8 | 464.6 | 415.8 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -213.1 | -163.5 | -236.9 | -255.9 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 268.53 | 226.3 | 227.7 | 159.9 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 962.21 | 1008.3 | 1050.2 | 1214.8 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 238.91 | 305.5 | 157 | 183.6 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 723.3 | 702.8 | 893.2 | 1031.2 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 166.1 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 19.27 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 498.87 | 491.6 | 711.2 | 776.1 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 737.77 | 797.1 | 868.2 | 959.7 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 14.77 | 14.2 | 15.2 | 16.8 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 214.73 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -0.99 | -1 | 99.2 | 82.7 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 53.63 | 241.5 | -4 | 0.3 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0.2 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 52.83 | 145.7 | 161 | 134.8 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 348.88 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | 239.31 | 211.1 | 263.3 | 457.5 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | 292.94 | 452.6 | 259.4 | 457.8 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 22.25 | 49.9 | 31 | 36.5 | |||||||||||||||||||||||
income-statement-row.row.net-income | 284.9 | 416.7 | 234.4 | 425.9 |
Häufig gestellte Frage
Wie hoch ist die Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Gesamtvermögen?
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) Gesamtvermögen ist 6277761845.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 482153895.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.752.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.261.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.296.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.249.
Was ist der Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 416691942.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 37593280.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 491631884.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 643139595.000.